What UK DSUR Transparency Expectations Mean for Sponsors

The Development Safety Update Report (DSUR) is one of the most important annual safety deliverables during clinical development. It provides regulators with an integrated view of the safety profile of an investigational drug, including cumulative knowledge, interval safety information, emerging risks and the sponsor’s ongoing assessment of participant safety.

For sponsors submitting DSURs in the United Kingdom, the report also needs to address region-specific transparency expectations. These expectations are designed to help regulators understand not only what safety information was identified during the reporting period, but how that information was collected, reviewed, evaluated and acted upon.

Why transparency matters in DSUR preparation

ICH E2F positions the DSUR as a common standard for periodic safety reporting on drugs under development. The UK transparency expectations add an important practical layer: sponsors should be able to explain the safety review process behind the report, including how safety data were recorded and reviewed in the context of the cumulative safety profile.

This shifts the DSUR from a static annual document to evidence of an active safety surveillance process. A strong DSUR should therefore show that the sponsor has maintained appropriate oversight throughout the reporting period, not only assembled information at the end of it.

What sponsors should be able to demonstrate

• Clear data provenance: Where safety data came from, how they were captured and how they were reconciled for inclusion in the report.
• Documented safety review: How safety information was assessed during the reporting period, including cumulative review and medical evaluation.
• Transparent signal status: Whether safety signals were newly identified, ongoing, closed or still under evaluation, with enough context to support the classification.
• Appropriate governance: How safety discussions, escalation pathways, safety meetings, protocol amendments or risk mitigation activities were documented.
• Consistency across documents: How DSUR content aligns with the Investigator’s Brochure, protocol, informed consent materials and emerging Risk Management Plan considerations.

Common challenges for sponsors

DSUR preparation becomes challenging when source data are dispersed across clinical, pharmacovigilance, medical review, regulatory and partner systems. It is also difficult when safety decisions are made throughout the year but are not documented in a way that can easily be translated into the annual report.

Sponsors may also struggle to present signal evaluation clearly. A signal that is closed, ongoing or awaiting further data should be described in a way that is concise, transparent and clinically meaningful. Tables can help, but only when supported by robust underlying review and consistent terminology.

How PrimeVigilance supports DSUR transparency

PrimeVigilance supports sponsors with DSUR preparation that is structured, transparent and aligned with global and region-specific expectations. Our approach connects aggregate report writing with medical review, signal evaluation, safety data analysis, quality control and cross-functional document alignment.

Support may include DSUR planning, data request coordination, safety data review, signal status tabulation, cumulative safety assessment, UK-specific section development, quality review and preparation of clear, submission-ready report content.

The objective is to help sponsors produce DSURs that are not only complete, but defensible: reports that clearly show how safety information was monitored and evaluated during the reporting period.

Conclusion

UK DSUR transparency expectations reinforce a broader regulatory direction: sponsors should be able to demonstrate active safety oversight, not simply annual reporting compliance. For investigational drugs, this level of transparency strengthens regulator confidence, supports participant protection and reduces the risk of avoidable clarification requests.

PrimeVigilance helps sponsors prepare DSURs that reflect disciplined safety governance, clear signal evaluation and region-specific reporting expectations.

Preparing a DSUR for UK submission or looking to strengthen your annual safety reporting process? Speak to PrimeVigilance about transparent, submission-ready DSUR support.

 

Author

Dhiraj Rajak, Medical Writer I

 

Recommended source links

Use these as external links or internal fact-check references before publication.

• ICH E2F – Development Safety Update Report: https://database.ich.org/sites/default/files/E2F_Guideline.pdf
• MHRA/Health Canada – DSUR transparency guidance: https://www.gov.uk/guidance/clinical-trials-for-medicines-manage-your-authorisation-report-safety-issues